MYGNMyriad Genetics, Inc.

$454M

Q1 2017 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$197M+3.4% YoY

Gross Profit

$153M77.5% margin

Operating Income

$13M6.6% margin

Net Income

$4M2.1% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

$41M

Free Cash Flow

$40M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$520M

Stockholders' Equity

$748M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$191M	+3.4%
Gross Profit	$153M	$150M	+1.5%
Operating Income	$13M	$43M	-69.7%
Net Income	$4M	$33M	-87.1%

Revenue Segments

Diagnostics

$185M94%

All Other Segments

$12M6%

MYGN Q1 2017 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena